1 – 10 of 10
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2005
-
Mark
Dose-Fractionated Radioimmunotherapy in Non-Hodgkin's Lymphoma Using DOTA-Conjugated, 90Y-Radiolabeled, Humanized Anti-CD22 Monoclonal Antibody, Epratuzumab.
(
- Contribution to journal › Article
-
Mark
Evaluation of methods for red marrow dosimetry based on patients undergoing radioimmunotherapy.
(
- Contribution to journal › Article
-
Mark
Internal microdosimetry for single cells in radioimmunotherapy of B-cell lymphoma.
(
- Contribution to journal › Article
- 2004
-
Mark
Evaluation of parameters influencing s values in mouse dosimetry.
(
- Contribution to journal › Article
- 2003
-
Mark
Change in Tumor-absorbed Dose due to Decrease in Mass during Fractionated Radioimmunotherapy in Lymphoma Patients.
(
- Contribution to journal › Article
- 2002
-
Mark
Time dependence of the activity concentration ratio of red marrow to blood and implications for red marrow dosimetry.
(
- Contribution to journal › Article
-
Mark
131I-labelled anti-CD22 MAb (LL2) in patients with B-cell lymphomas failing chemotherapy. Treatment outcome, haematological toxicity and bone marrow absorbed dose estimates.
(
- Contribution to journal › Article
-
Mark
Single tumor cell uptake and dosimetry of technetium-99m Fab ' anti-CD22 in low-grade B-cell lymphoma
(
- Contribution to journal › Article
- 2001
-
Mark
Durable response to 90-yttrium-Epratuzumab (hLL2) in B-cell lymphoma failing chemotherapy by using dose-fractionation schedule
(
- Contribution to journal › Article
- 2000
-
Mark
Extracorporeal techniques in radioimmunotherapy
2000) p.223-243(
- Chapter in Book/Report/Conference proceeding › Book chapter